Journal Article
. 2008 Mar; 205(4):825-39.
doi: 10.1084/jem.20071341.

OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection

Silvia Piconese 1 Barbara Valzasina  Mario P Colombo  
  • PMID: 18362171
  •     60 References
  •     171 citations


Regulatory T (T reg) cells are the major obstacle to cancer immunotherapy, and their depletion promptly induces conversion of peripheral precursors into T reg cells. We show that T reg cells can be functionally inactivated by OX40 triggering. In tumors, the vast majority of CD4(+) T cells are Foxp3(+) and OX40(bright). However, intratumor injection of the agonist anti-OX40 monoclonal antibody (mAb) OX86, but not anti-CD25 mAb, induces tumor rejection in 80% of mice, an effect that is abrogated by CD8 depletion. Upon intratumor OX40 triggering, increased numbers of infiltrating dendritic cells (DCs) migrate to draining lymph nodes and generate a new wave of tumor-specific cytotoxic T lymphocytes, as detected by tetramer and CD44 staining of node CD8(+) T lymphocytes. Tumor-bearing Rag1-knockout (KO) mice reconstituted with OX40-deficient T reg cells and wild-type (WT) effector T cells, or the reciprocal combination, showed that both T reg and effector T cells must be triggered via OX40 for the tumor to be rejected. Accordingly, WT but not OX40-KO mice receiving intratumor coinjection of OX86 and ovalbumin protein were able to revert tumor-induced tolerization of adoptively transferred OX40-competent OTII T lymphocytes. In conclusion, OX40-mediated inactivation of T reg cell function unleashes nearby DCs, allowing them to induce an adaptive immune response. In addition, the known OX40-dependent delivery of fitness signals to activated T cells is boosted by concurrent T reg cell inhibition. OX40 triggering thus has multiple effects that converge to mediate tumor rejection.

The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion.
I Gramaglia, A Jember, +3 authors, M Croft.
J Immunol, 2000 Sep 07; 165(6). PMID: 10975814
Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells.
Kuibeom Ko, Sayuri Yamazaki, +7 authors, Shimon Sakaguchi.
J Exp Med, 2005 Sep 28; 202(7). PMID: 16186187    Free PMC article.
Highly Cited.
Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice.
Qizhi Tang, Jason Y Adams, +7 authors, Jeffrey A Bluestone.
Nat Immunol, 2005 Nov 29; 7(1). PMID: 16311599    Free PMC article.
Highly Cited.
Imaging the function of regulatory T cells in vivo.
Qizhi Tang, Matthew F Krummel.
Curr Opin Immunol, 2006 Jun 13; 18(4). PMID: 16765579
Comment on "Cutting edge: anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+CD25+ T regulatory cells".
Santiago Zelenay, Jocelyne Demengeot.
J Immunol, 2006 Aug 05; 177(4). PMID: 16887957
Gene structure and chromosomal assignment of mouse GITR, a member of the tumor necrosis factor/nerve growth factor receptor family.
G Nocentini, A Bartoli, +5 authors, C Riccardi.
DNA Cell Biol, 2000 May 08; 19(4). PMID: 10798444
Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25- lymphocytes is thymus and proliferation independent.
Barbara Valzasina, Silvia Piconese, Cristiana Guiducci, Mario P Colombo.
Cancer Res, 2006 Apr 19; 66(8). PMID: 16618776
Regulatory T cells, tumour immunity and immunotherapy.
Weiping Zou.
Nat Rev Immunol, 2006 Mar 25; 6(4). PMID: 16557261
Highly Cited. Review.
Regulatory T cells inhibit stable contacts between CD4+ T cells and dendritic cells in vivo.
Carlos E Tadokoro, Guy Shakhar, +5 authors, Michael L Dustin.
J Exp Med, 2006 Mar 15; 203(3). PMID: 16533880    Free PMC article.
Highly Cited.
OX40 ligand-transduced tumor cell vaccine synergizes with GM-CSF and requires CD40-Apc signaling to boost the host T cell antitumor response.
Giorgia Gri, Elena Gallo, +2 authors, Mario P Colombo.
J Immunol, 2002 Dec 24; 170(1). PMID: 12496388
Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth.
J Kjaergaard, J Tanaka, +3 authors, S Shu.
Cancer Res, 2000 Oct 18; 60(19). PMID: 11034096
Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines.
Gang Zhou, Charles G Drake, Hyam I Levitsky.
Blood, 2005 Sep 24; 107(2). PMID: 16179369    Free PMC article.
Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40.
Kazuo Sugamura, Naoto Ishii, Andrew D Weinberg.
Nat Rev Immunol, 2004 Jun 03; 4(6). PMID: 15173831
Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state.
T Takahashi, Y Kuniyasu, +5 authors, S Sakaguchi.
Int Immunol, 1999 Jan 14; 10(12). PMID: 9885918
Highly Cited.
Activated T cells express the OX40 ligand: requirements for induction and costimulatory function.
Itzhak Mendel, Ethan M Shevach.
Immunology, 2006 Jan 21; 117(2). PMID: 16423055    Free PMC article.
CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner.
François Ghiringhelli, Cédric Ménard, +19 authors, Laurence Zitvogel.
J Exp Med, 2005 Oct 19; 202(8). PMID: 16230475    Free PMC article.
Highly Cited.
Activated CD4+CD25+ T cells selectively kill B lymphocytes.
Dong-Mei Zhao, Angela M Thornton, Richard J DiPaolo, Ethan M Shevach.
Blood, 2006 Jan 19; 107(10). PMID: 16418326    Free PMC article.
Highly Cited.
The tumor-draining lymph node as an immune-privileged site.
David H Munn, Andrew L Mellor.
Immunol Rev, 2006 Sep 16; 213. PMID: 16972902
Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody.
Alain P Vicari, Claudia Chiodoni, +10 authors, Christophe Caux.
J Exp Med, 2002 Aug 21; 196(4). PMID: 12186845    Free PMC article.
Chemokine receptor CCR7 required for T lymphocyte exit from peripheral tissues.
Gudrun F Debes, Carrie N Arnold, +4 authors, Eugene C Butcher.
Nat Immunol, 2005 Aug 24; 6(9). PMID: 16116468    Free PMC article.
Highly Cited.
Distinct and overlapping roles of interleukin-10 and CD25+ regulatory T cells in the inhibition of antitumor CD8 T-cell responses.
Christophe Dercamp, Karine Chemin, +2 authors, Alain P Vicari.
Cancer Res, 2005 Sep 17; 65(18). PMID: 16166328
Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity.
J Shimizu, S Yamazaki, S Sakaguchi.
J Immunol, 1999 Nov 24; 163(10). PMID: 10553041
Highly Cited.
CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs.
R Förster, A Schubel, +4 authors, M Lipp.
Cell, 1999 Oct 16; 99(1). PMID: 10520991
Highly Cited.
The GITR-GITRL interaction: co-stimulation or contrasuppression of regulatory activity?
Ethan M Shevach, Geoffrey L Stephens.
Nat Rev Immunol, 2006 Jul 27; 6(8). PMID: 16868552
Immunostimulatory monoclonal antibodies for cancer therapy.
Ignacio Melero, Sandra Hervas-Stubbs, +2 authors, Lieping Chen.
Nat Rev Cancer, 2007 Jan 26; 7(2). PMID: 17251916
Highly Cited. Review.
OX40 costimulation turns off Foxp3+ Tregs.
Minh Diem Vu, Xiang Xiao, +6 authors, Xian Chang Li.
Blood, 2007 Jun 19; 110(7). PMID: 17575071    Free PMC article.
Highly Cited.
Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice.
Emma Jones, Michaela Dahm-Vicker, +4 authors, Awen Gallimore.
Cancer Immun, 2003 May 16; 2. PMID: 12747746
Distinct roles for the OX40-OX40 ligand interaction in regulatory and nonregulatory T cells.
Ikuo Takeda, Shoji Ine, +5 authors, Naoto Ishii.
J Immunol, 2004 Mar 09; 172(6). PMID: 15004159
Highly Cited.
Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy.
Mario P Colombo, Silvia Piconese.
Nat Rev Cancer, 2007 Oct 25; 7(11). PMID: 17957190
Highly Cited. Review.
Both regulatory T cells and antitumor effector T cells are primed in the same draining lymph nodes during tumor progression.
Toru Hiura, Hiroshi Kagamu, +5 authors, Hirohisa Yoshizawa.
J Immunol, 2005 Oct 08; 175(8). PMID: 16210609
Cutting edge: OX40 inhibits TGF-beta- and antigen-driven conversion of naive CD4 T cells into CD25+Foxp3+ T cells.
Takanori So, Michael Croft.
J Immunol, 2007 Jul 21; 179(3). PMID: 17641007
CD4+CD25+ regulatory T cells limit the risk of autoimmune disease arising from T cell receptor crossreactivity.
Leigh A Stephens, David Gray, Stephen M Anderton.
Proc Natl Acad Sci U S A, 2005 Nov 17; 102(48). PMID: 16287973    Free PMC article.
Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation.
François Ghiringhelli, Pierre E Puig, +7 authors, Laurence Zitvogel.
J Exp Med, 2005 Sep 28; 202(7). PMID: 16186184    Free PMC article.
Highly Cited.
Competition controls the rate of transition between the peripheral pools of CD4+CD25- and CD4+CD25+ T cells.
Afonso R M Almeida, Bruno Zaragoza, Antonio A Freitas.
Int Immunol, 2006 Sep 22; 18(11). PMID: 16987936
Chemokine receptor CCR7 guides T cell exit from peripheral tissues and entry into afferent lymphatics.
Shannon K Bromley, Seddon Y Thomas, Andrew D Luster.
Nat Immunol, 2005 Aug 24; 6(9). PMID: 16116469
Highly Cited.
CD4+ CD25+ T cells with the phenotypic and functional characteristics of regulatory T cells are enriched in the synovial fluid of patients with rheumatoid arthritis.
M Möttönen, J Heikkinen, +3 authors, O Lassila.
Clin Exp Immunol, 2005 Apr 06; 140(2). PMID: 15807863    Free PMC article.
Cooperation between CD4 and CD8 T cells for anti-tumor activity is enhanced by OX40 signals.
Aihua Song, Jianxun Song, Xiaohong Tang, Michael Croft.
Eur J Immunol, 2007 Apr 13; 37(5). PMID: 17429847
Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors.
Ping Yu, Youjin Lee, +4 authors, Yang-Xin Fu.
J Exp Med, 2005 Mar 09; 201(5). PMID: 15753211    Free PMC article.
Highly Cited.
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.
Tyler J Curiel, George Coukos, +18 authors, Weiping Zou.
Nat Med, 2004 Aug 24; 10(9). PMID: 15322536
Highly Cited.
OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases.
Ping-Ying Pan, Yunjuan Zang, +2 authors, Shu-Hsia Chen.
Mol Ther, 2002 Oct 16; 6(4). PMID: 12377195
A signal through OX40 (CD134) allows anergic, autoreactive T cells to acquire effector cell functions.
Stephanie K Lathrop, Cortny A Huddleston, +3 authors, David C Parker.
J Immunol, 2004 May 22; 172(11). PMID: 15153490
Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity.
Teresa Ramirez-Montagut, Andrew Chow, +7 authors, Marcel R M van den Brink.
J Immunol, 2006 May 20; 176(11). PMID: 16709800
Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity.
Adam D Cohen, Adi Diab, +9 authors, Alan N Houghton.
Cancer Res, 2006 May 03; 66(9). PMID: 16651447    Free PMC article.
OX40-OX40 ligand interaction through T cell-T cell contact contributes to CD4 T cell longevity.
Pejman Soroosh, Shouji Ine, Kazuo Sugamura, Naoto Ishii.
J Immunol, 2006 May 04; 176(10). PMID: 16670306
Engagement of the OX-40 receptor in vivo enhances antitumor immunity.
A D Weinberg, M M Rivera, +7 authors, J Shields.
J Immunol, 2000 Feb 05; 164(4). PMID: 10657670
Highly Cited.
Signaling through OX40 (CD134) breaks peripheral T-cell tolerance.
P Bansal-Pakala, A G Jember, M Croft.
Nat Med, 2001 Aug 02; 7(8). PMID: 11479622
Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance.
Jun Shimizu, Sayuri Yamazaki, +2 authors, Shimon Sakaguchi.
Nat Immunol, 2002 Jan 29; 3(2). PMID: 11812990
Highly Cited.
OX40 (CD134) engagement drives differentiation of CD4+ T cells to effector cells.
Cortny A Huddleston, Andrew D Weinberg, David C Parker.
Eur J Immunol, 2006 Mar 17; 36(5). PMID: 16541471
Regulatory T cells inhibit Fas ligand-induced innate and adaptive tumour immunity.
Anna Katharina Simon, Emma Jones, +5 authors, Awen Gallimore.
Eur J Immunol, 2007 Feb 13; 37(3). PMID: 17294404    Free PMC article.
Tumor-derived CD4(+)CD25(+) regulatory T cell suppression of dendritic cell function involves TGF-beta and IL-10.
Nicolas Larmonier, Marilyn Marron, +7 authors, Emmanuel Katsanis.
Cancer Immunol Immunother, 2006 Apr 14; 56(1). PMID: 16612596
The three Es of cancer immunoediting.
Gavin P Dunn, Lloyd J Old, Robert D Schreiber.
Annu Rev Immunol, 2004 Mar 23; 22. PMID: 15032581
Highly Cited. Review.
Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance.
Gang Zhou, Hyam I Levitsky.
J Immunol, 2007 Feb 06; 178(4). PMID: 17277120
Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens.
Denise Golgher, Emma Jones, +2 authors, Awen Gallimore.
Eur J Immunol, 2003 Jan 31; 32(11). PMID: 12555672
OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T cell tolerance to an endogenous tumor antigen.
Satoshi Murata, Brian H Ladle, +8 authors, R Todd Reilly.
J Immunol, 2006 Jan 06; 176(2). PMID: 16393983
Cancer despite immunosurveillance: immunoselection and immunosubversion.
Laurence Zitvogel, Antoine Tesniere, Guido Kroemer.
Nat Rev Immunol, 2006 Sep 16; 6(10). PMID: 16977338
Highly Cited. Review.
Costimulation of CD8 T cell responses by OX40.
Pratima Bansal-Pakala, Beth S Halteman, Mary Huey-Yu Cheng, Michael Croft.
J Immunol, 2004 Apr 07; 172(8). PMID: 15067059
OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells.
P R Rogers, J Song, +2 authors, M Croft.
Immunity, 2001 Sep 25; 15(3). PMID: 11567634
Highly Cited.
Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR.
Barbara Valzasina, Cristiana Guiducci, +3 authors, Mario P Colombo.
Blood, 2004 Dec 14; 105(7). PMID: 15591118
Highly Cited.
Modulation of dendritic cell function by naive and regulatory CD4+ T cells.
Marc Veldhoen, Halima Moncrieffe, +2 authors, Brigitta Stockinger.
J Immunol, 2006 May 04; 176(10). PMID: 16670330
CCR7 is required for the in vivo function of CD4+ CD25+ regulatory T cells.
Martin A Schneider, Josef G Meingassner, +2 authors, Antal Rot.
J Exp Med, 2007 Mar 21; 204(4). PMID: 17371928    Free PMC article.
Highly Cited.
Regulatory T cells and treatment of cancer.
Tyler J Curiel.
Curr Opin Immunol, 2008 May 30; 20(2). PMID: 18508251    Free PMC article.
CD28 costimulation is essential for human T regulatory expansion and function.
Tatiana N Golovina, Tatiana Mikheeva, +12 authors, James L Riley.
J Immunol, 2008 Aug 08; 181(4). PMID: 18684977    Free PMC article.
FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions.
Mojgan Ahmadzadeh, Aloisio Felipe-Silva, +4 authors, Steven A Rosenberg.
Blood, 2008 Sep 30; 112(13). PMID: 18820132    Free PMC article.
Dendritic cells: a critical player in cancer therapy?
Anna Karolina Palucka, Hideki Ueno, Joseph Fay, Jacques Banchereau.
J Immunother, 2008 Oct 04; 31(9). PMID: 18833008    Free PMC article.
T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy.
Roch Houot, Ronald Levy.
Blood, 2008 Oct 23; 113(15). PMID: 18941113    Free PMC article.
The Critical Role of TGF-beta1 in the Development of Induced Foxp3+ Regulatory T Cells.
Song Guo Zheng.
Int J Clin Exp Med, 2008 Dec 17; 1(3). PMID: 19079658    Free PMC article.
OX40 costimulation prevents allograft acceptance induced by CD40-CD40L blockade.
Bryna E Burrell, Guanyi Lu, Xian C Li, D Keith Bishop.
J Immunol, 2008 Dec 26; 182(1). PMID: 19109169    Free PMC article.
Regulatory T cells overturned: the effectors fight back.
Lucy S K Walker.
Immunology, 2009 Mar 13; 126(4). PMID: 19278420    Free PMC article.
The role of TNF superfamily members in T-cell function and diseases.
Michael Croft.
Nat Rev Immunol, 2009 Mar 26; 9(4). PMID: 19319144    Free PMC article.
Highly Cited. Review.
Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes.
Madhav D Sharma, De-Yan Hou, +6 authors, David H Munn.
Blood, 2009 Apr 16; 113(24). PMID: 19366986    Free PMC article.
Highly Cited.
T-regulatory cell modulation: the future of cancer immunotherapy?
S Nizar, J Copier, +4 authors, A Dalgleish.
Br J Cancer, 2009 Apr 23; 100(11). PMID: 19384299    Free PMC article.
OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis.
Daniel Hirschhorn-Cymerman, Gabrielle A Rizzuto, +6 authors, Alan N Houghton.
J Exp Med, 2009 May 06; 206(5). PMID: 19414558    Free PMC article.
The significance of OX40 and OX40L to T-cell biology and immune disease.
Michael Croft, Takanori So, Wei Duan, Pejman Soroosh.
Immunol Rev, 2009 May 12; 229(1). PMID: 19426222    Free PMC article.
Highly Cited. Review.
Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors.
Rajesh K Sharma, Kutlu G Elpek, +4 authors, Haval Shirwan.
Cancer Res, 2009 May 14; 69(10). PMID: 19435920    Free PMC article.
Cooperation between molecular targets of costimulation in promoting T cell persistence and tumor regression.
Baohua Zhao, Aihua Song, +6 authors, Jianxun Song.
J Immunol, 2009 May 21; 182(11). PMID: 19454669    Free PMC article.
OX40 costimulation can abrogate Foxp3+ regulatory T cell-mediated suppression of antitumor immunity.
Naomi Kitamura, Satoshi Murata, +4 authors, Tohru Tani.
Int J Cancer, 2009 May 21; 125(3). PMID: 19455675    Free PMC article.
The role of OX40-mediated co-stimulation in T-cell activation and survival.
William L Redmond, Carl E Ruby, Andrew D Weinberg.
Crit Rev Immunol, 2009 Jun 23; 29(3). PMID: 19538134    Free PMC article.
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies.
Karl S Peggs, Sergio A Quezada, +2 authors, James P Allison.
J Exp Med, 2009 Jul 08; 206(8). PMID: 19581407    Free PMC article.
Highly Cited.
Infiltrating CTLs in human glioblastoma establish immunological synapses with tumorigenic cells.
Carlos Barcia, Aurora Gómez, +5 authors, Maria-Trinidad Herrero.
Am J Pathol, 2009 Jul 25; 175(2). PMID: 19628762    Free PMC article.
Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion.
Roch Houot, Matthew J Goldstein, +8 authors, Ronald Levy.
Blood, 2009 Jul 31; 114(16). PMID: 19641184    Free PMC article.
PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells.
Wenshi Wang, Roy Lau, +3 authors, Jeffrey Weber.
Int Immunol, 2009 Aug 05; 21(9). PMID: 19651643    Free PMC article.
Highly Cited.
Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists.
K S Peggs, S A Quezada, J P Allison.
Clin Exp Immunol, 2009 Aug 08; 157(1). PMID: 19659765    Free PMC article.
Ligation of the OX40 co-stimulatory receptor reverses self-Ag and tumor-induced CD8 T-cell anergy in vivo.
William L Redmond, Michael J Gough, Andrew D Weinberg.
Eur J Immunol, 2009 Aug 13; 39(8). PMID: 19672905    Free PMC article.
Cancer immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effects.
Ulf Petrausch, Christian H Poehlein, +20 authors, Bernard A Fox.
Curr Mol Med, 2009 Aug 20; 9(6). PMID: 19689294    Free PMC article.
Integrating costimulatory agonists to optimize immune-based cancer therapies.
Angela D Pardee, Amy K Wesa, Walter J Storkus.
Immunotherapy, 2010 Jan 05; 1(2). PMID: 20046961    Free PMC article.
Control of immunity by the TNFR-related molecule OX40 (CD134).
Michael Croft.
Annu Rev Immunol, 2010 Mar 24; 28. PMID: 20307208    Free PMC article.
Highly Cited. Review.
OX40 is required for regulatory T cell-mediated control of colitis.
Thibault Griseri, Mark Asquith, Claire Thompson, Fiona Powrie.
J Exp Med, 2010 Apr 07; 207(4). PMID: 20368580    Free PMC article.
Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation.
Adam D Cohen, David A Schaer, +10 authors, Jedd D Wolchok.
PLoS One, 2010 May 11; 5(5). PMID: 20454651    Free PMC article.
Highly Cited.
Adjuvant therapy with agonistic antibodies to CD134 (OX40) increases local control after surgical or radiation therapy of cancer in mice.
Michael J Gough, Marka R Crittenden, +7 authors, Andrew D Weinberg.
J Immunother, 2010 Sep 16; 33(8). PMID: 20842057    Free PMC article.
Therapeutic Treg expansion in mice by TNFRSF25 prevents allergic lung inflammation.
Taylor H Schreiber, Dietlinde Wolf, +6 authors, Eckhard R Podack.
J Clin Invest, 2010 Oct 05; 120(10). PMID: 20890040    Free PMC article.
A therapeutic OX40 agonist dynamically alters dendritic, endothelial, and T cell subsets within the established tumor microenvironment.
Angela D Pardee, Dustin McCurry, +3 authors, Walter J Storkus.
Cancer Res, 2010 Nov 04; 70(22). PMID: 21045144    Free PMC article.
Signaling through OX40 enhances antitumor immunity.
Shawn M Jensen, Levi D Maston, +16 authors, Bernard A Fox.
Semin Oncol, 2010 Nov 16; 37(5). PMID: 21074068    Free PMC article.
HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma.
Daniela Buglio, Noor M Khaskhely, +3 authors, Anas Younes.
Blood, 2011 Jan 18; 117(10). PMID: 21239696    Free PMC article.
2011: the immune hallmarks of cancer.
Federica Cavallo, Carla De Giovanni, +2 authors, Pier-Luigi Lollini.
Cancer Immunol Immunother, 2011 Jan 27; 60(3). PMID: 21267721    Free PMC article.
Highly Cited.
Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation.
Alexander Pedroza-Gonzalez, Kangling Xu, +14 authors, A Karolina Palucka.
J Exp Med, 2011 Feb 23; 208(3). PMID: 21339324    Free PMC article.
Highly Cited.
Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication.
Sergio A Quezada, Karl S Peggs, Tyler R Simpson, James P Allison.
Immunol Rev, 2011 Apr 15; 241(1). PMID: 21488893    Free PMC article.
Highly Cited. Review.
TNF optimally activatives regulatory T cells by inducing TNF receptor superfamily members TNFR2, 4-1BB and OX40.
Ryoko Hamano, Jiaqiang Huang, +2 authors, Xin Chen.
Eur J Immunol, 2011 Apr 15; 41(7). PMID: 21491419    Free PMC article.
Signals through 4-1BB inhibit T regulatory cells by blocking IL-9 production enhancing antitumor responses.
Shannon E Smith, Dominique B Hoelzinger, +2 authors, Joseph Lustgarten.
Cancer Immunol Immunother, 2011 Jul 27; 60(12). PMID: 21789593    Free PMC article.
Targeting 4-1BB costimulation to disseminated tumor lesions with bi-specific oligonucleotide aptamers.
Fernando Pastor, Despina Kolonias, James O McNamara, Eli Gilboa.
Mol Ther, 2011 Aug 11; 19(10). PMID: 21829171    Free PMC article.
The small molecule TGF-β signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis.
Kendra Garrison, Tobias Hahn, +3 authors, Emmanuel T Akporiaye.
Cancer Immunol Immunother, 2011 Oct 06; 61(4). PMID: 21971588    Free PMC article.
NF-κB–inducing kinase plays an essential T cell–intrinsic role in graft-versus-host disease and lethal autoimmunity in mice.
Susan E Murray, Fanny Polesso, +5 authors, David C Parker.
J Clin Invest, 2011 Nov 03; 121(12). PMID: 22045568    Free PMC article.
Antigen-specific prevention of type 1 diabetes in NOD mice is ameliorated by OX40 agonist treatment.
Damien Bresson, Georgia Fousteri, +2 authors, Matthias von Herrath.
J Autoimmun, 2011 Nov 09; 37(4). PMID: 22063316    Free PMC article.
Immunotherapy with IL-10- and IFN-γ-producing CD4 effector cells modulate "Natural" and "Inducible" CD4 TReg cell subpopulation levels: observations in four cases of patients with ovarian cancer.
Mark J Dobrzanski, Kathleen A Rewers-Felkins, +5 authors, Stephen E Wright.
Cancer Immunol Immunother, 2011 Nov 16; 61(6). PMID: 22083345    Free PMC article.
New insights on OX40 in the control of T cell immunity and immune tolerance in vivo.
Xiang Xiao, Weihua Gong, +6 authors, Xian C Li.
J Immunol, 2011 Dec 08; 188(2). PMID: 22147766    Free PMC article.
Modulation of GITR for cancer immunotherapy.
David A Schaer, Judith T Murphy, Jedd D Wolchok.
Curr Opin Immunol, 2012 Jan 17; 24(2). PMID: 22245556    Free PMC article.
Targeting regulatory T cells.
Christine Ménétrier-Caux, Tyler Curiel, +3 authors, Weiping Zou.
Target Oncol, 2012 Feb 14; 7(1). PMID: 22327882
Fine-tuning of dendritic cell biology by the TNF superfamily.
Leslie Summers deLuca, Jennifer L Gommerman.
Nat Rev Immunol, 2012 Apr 11; 12(5). PMID: 22487654
The ambiguity in immunology.
Vincenzo Barnaba, Marino Paroli, Silvia Piconese.
Front Immunol, 2012 May 09; 3. PMID: 22566903    Free PMC article.
Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer.
Helene Pere, Corinne Tanchot, +17 authors, Eric Tartour.
Oncoimmunology, 2012 Jun 28; 1(3). PMID: 22737608    Free PMC article.
Towards curative cancer immunotherapy: overcoming posttherapy tumor escape.
Gang Zhou, Hyam Levitsky.
Clin Dev Immunol, 2012 Jul 11; 2012. PMID: 22778760    Free PMC article.
OX40 signaling favors the induction of T(H)9 cells and airway inflammation.
Xiang Xiao, Savithri Balasubramanian, +7 authors, Xian Chang Li.
Nat Immunol, 2012 Jul 31; 13(10). PMID: 22842344    Free PMC article.
Highly Cited.
SA-4-1BBL costimulation inhibits conversion of conventional CD4+ T cells into CD4+ FoxP3+ T regulatory cells by production of IFN-γ.
Shravan Madireddi, Rich-Henry Schabowsky, +3 authors, Haval Shirwan.
PLoS One, 2012 Aug 08; 7(8). PMID: 22870329    Free PMC article.
The Role of the PI3K Signaling Pathway in CD4(+) T Cell Differentiation and Function.
Jonathan M Han, Scott J Patterson, Megan K Levings.
Front Immunol, 2012 Aug 21; 3. PMID: 22905034    Free PMC article.
Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype.
Daniel Hirschhorn-Cymerman, Sadna Budhu, +10 authors, Jedd D Wolchok.
J Exp Med, 2012 Sep 26; 209(11). PMID: 23008334    Free PMC article.
Th9 cells promote antitumor immune responses in vivo.
Yong Lu, Sungyoul Hong, +10 authors, Qing Yi.
J Clin Invest, 2012 Oct 16; 122(11). PMID: 23064366    Free PMC article.
Highly Cited.
Advances in targeting cell surface signalling molecules for immune modulation.
Sheng Yao, Yuwen Zhu, Lieping Chen.
Nat Rev Drug Discov, 2013 Feb 02; 12(2). PMID: 23370250    Free PMC article.
Highly Cited. Review.
Influence of tumors on protective anti-tumor immunity and the effects of irradiation.
Gemma A Foulds, Jürgen Radons, +2 authors, Alan G Pockley.
Front Oncol, 2013 Feb 05; 3. PMID: 23378947    Free PMC article.
The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy.
Amy E Moran, Magdalena Kovacsovics-Bankowski, Andrew D Weinberg.
Curr Opin Immunol, 2013 Feb 19; 25(2). PMID: 23414607    Free PMC article.
Dysregulation of CD4+CD25(high) T cells in the synovial fluid of patients with antibiotic-refractory Lyme arthritis.
Nalini K Vudattu, Klemen Strle, Allen C Steere, Elise E Drouin.
Arthritis Rheum, 2013 Mar 02; 65(6). PMID: 23450683    Free PMC article.
Agonist antibodies to TNFR molecules that costimulate T and NK cells.
Ignacio Melero, Daniel Hirschhorn-Cymerman, +2 authors, Jedd D Wolchok.
Clin Cancer Res, 2013 Mar 06; 19(5). PMID: 23460535    Free PMC article.
Highly Cited.
Interaction between natural killer cells and regulatory T cells: perspectives for immunotherapy.
Isabela Pedroza-Pacheco, Alejandro Madrigal, Aurore Saudemont.
Cell Mol Immunol, 2013 Mar 26; 10(3). PMID: 23524654    Free PMC article.
Modulation of tumor immunity by soluble and membrane-bound molecules at the immunological synapse.
Pablo A González, Leandro J Carreño, +3 authors, Alexis M Kalergis.
Clin Dev Immunol, 2013 Mar 28; 2013. PMID: 23533456    Free PMC article.
Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects.
John Stagg, Bertrand Allard.
Ther Adv Med Oncol, 2013 May 02; 5(3). PMID: 23634195    Free PMC article.
Targeting Tregs in Malignant Brain Cancer: Overcoming IDO.
Derek A Wainwright, Mahua Dey, Alan Chang, Maciej S Lesniak.
Front Immunol, 2013 May 31; 4. PMID: 23720663    Free PMC article.
Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy.
Edwin Bremer.
ISRN Oncol, 2013 Jul 11; 2013. PMID: 23840967    Free PMC article.
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Tyler R Simpson, Fubin Li, +11 authors, Sergio A Quezada.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897981    Free PMC article.
Highly Cited.
Immunomodulation via Chemotherapy and Targeted Therapy: A New Paradigm in Breast Cancer Therapy?
John Stagg, Fabrice Andre, Sherene Loi.
Breast Care (Basel), 2013 Aug 02; 7(4). PMID: 23904828    Free PMC article.
Antibodies targeting human OX40 expand effector T cells and block inducible and natural regulatory T cell function.
Kui S Voo, Laura Bover, +5 authors, Yong J Liu.
J Immunol, 2013 Sep 10; 191(7). PMID: 24014877    Free PMC article.
Secreted and transmembrane 1A is a novel co-stimulatory ligand.
Duncan Howie, Hugo Garcia Rueda, Marion H Brown, Herman Waldmann.
PLoS One, 2013 Sep 17; 8(9). PMID: 24039998    Free PMC article.
OX40 is a potent immune-stimulating target in late-stage cancer patients.
Brendan D Curti, Magdalena Kovacsovics-Bankowski, +20 authors, Andrew D Weinberg.
Cancer Res, 2013 Nov 02; 73(24). PMID: 24177180    Free PMC article.
Highly Cited.
Update on vaccine development for renal cell cancer.
Nina Chi, Jodi K Maranchie, Leonard J Appleman, Walter J Storkus.
Open Access J Urol, 2010 Jan 01; 2. PMID: 24198621    Free PMC article.
Intratumoral CD4+ T lymphodepletion sensitizes poorly immunogenic melanomas to immunotherapy with an OX40 agonist.
Susumu Fujiwara, Hiroshi Nagai, +3 authors, Chikako Nishigori.
J Invest Dermatol, 2014 Jan 29; 134(7). PMID: 24468748
Anaphylaxis caused by repetitive doses of a GITR agonist monoclonal antibody in mice.
Judith T Murphy, Andre P Burey, +4 authors, Jedd D Wolchok.
Blood, 2014 Feb 22; 123(14). PMID: 24558202    Free PMC article.
PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer.
Zhiqiang Guo, Xin Wang, +3 authors, Shulan Zhang.
PLoS One, 2014 Mar 04; 9(2). PMID: 24586709    Free PMC article.
Highly Cited.
Regulatory T-cell homeostasis: steady-state maintenance and modulation during inflammation.
Kate S Smigiel, Shivani Srivastava, J Michael Stolley, Daniel J Campbell.
Immunol Rev, 2014 Apr 10; 259(1). PMID: 24712458    Free PMC article.
Highly Cited. Review.
Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma.
Kui Shin Voo, Myriam Foglietta, +13 authors, Sattva S Neelapu.
Int J Cancer, 2014 Apr 29; 135(12). PMID: 24771328    Free PMC article.
Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity.
William L Redmond, Stefanie N Linch, Melissa J Kasiewicz.
Cancer Immunol Res, 2014 Apr 30; 2(2). PMID: 24778278    Free PMC article.
Opening a niche for therapy: local lymphodepletion helps the immune system to fight melanoma.
Karsten Mahnke, Alexander Skorokhod, Stefan Grabbe, Alexander H Enk.
J Invest Dermatol, 2014 Jun 14; 134(7). PMID: 24924759
Small-molecule modulators of the OX40-OX40 ligand co-stimulatory protein-protein interaction.
Yun Song, Emilio Margolles-Clark, Allison Bayer, Peter Buchwald.
Br J Pharmacol, 2014 Jun 17; 171(21). PMID: 24930776    Free PMC article.
The "Trojan Horse" approach to tumor immunotherapy: targeting the tumor microenvironment.
Delia Nelson, Scott Fisher, Bruce Robinson.
J Immunol Res, 2014 Jun 24; 2014. PMID: 24955376    Free PMC article.
p38 MAPK-inhibited dendritic cells induce superior antitumour immune responses and overcome regulatory T-cell-mediated immunosuppression.
Yong Lu, Mingjun Zhang, +9 authors, Qing Yi.
Nat Commun, 2014 Jun 25; 5. PMID: 24957461    Free PMC article.
Cancer immunotherapy in clinical practice -- the past, present, and future.
Gaurav Goel, Weijing Sun.
Chin J Cancer, 2014 Sep 06; 33(9). PMID: 25189717    Free PMC article.
OX40 ligand expressed in glioblastoma modulates adaptive immunity depending on the microenvironment: a clue for successful immunotherapy.
Ichiyo Shibahara, Ryuta Saito, +16 authors, Teiji Tominaga.
Mol Cancer, 2015 Mar 10; 14. PMID: 25744203    Free PMC article.
OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal.
Stefanie N Linch, Michael J McNamara, William L Redmond.
Front Oncol, 2015 Mar 13; 5. PMID: 25763356    Free PMC article.
Highly Cited. Review.
Regulatory T cells turn pathogenic.
Jitao Guo, Xuyu Zhou.
Cell Mol Immunol, 2015 May 06; 12(5). PMID: 25942597    Free PMC article.
Evolving synergistic combinations of targeted immunotherapies to combat cancer.
Ignacio Melero, David M Berman, +3 authors, John Haanen.
Nat Rev Cancer, 2015 Jul 25; 15(8). PMID: 26205340
Highly Cited. Review.
OX40, OX40L and Autoimmunity: a Comprehensive Review.
Gwilym J Webb, Gideon M Hirschfield, Peter J L Lane.
Clin Rev Allergy Immunol, 2015 Jul 29; 50(3). PMID: 26215166
Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites.
Powell Perng, Michael Lim.
Front Oncol, 2015 Jul 29; 5. PMID: 26217588    Free PMC article.
Concepts and mechanisms underlying chemotherapy induced immunogenic cell death: impact on clinical studies and considerations for combined therapies.
Simon Gebremeskel, Brent Johnston.
Oncotarget, 2015 Oct 22; 6(39). PMID: 26486085    Free PMC article.
Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1.
Amer Assal, Justin Kaner, Gopichand Pendurti, Xingxing Zang.
Immunotherapy, 2015 Nov 17; 7(11). PMID: 26567614    Free PMC article.
Immunostimulation by OX40 Ligand Transgenic Ewing Sarcoma Cells.
Dajana Reuter, Martin S Staege, Caspar D Kühnöl, Jürgen Föll.
Front Oncol, 2015 Nov 19; 5. PMID: 26579494    Free PMC article.
Pathogen-Associated Molecular Patterns Induced Crosstalk between Dendritic Cells, T Helper Cells, and Natural Killer Helper Cells Can Improve Dendritic Cell Vaccination.
Tammy Oth, Joris Vanderlocht, +2 authors, Wilfred T V Germeraad.
Mediators Inflamm, 2016 Mar 17; 2016. PMID: 26980946    Free PMC article.
OX40+ Regulatory T Cells in Cutaneous Squamous Cell Carcinoma Suppress Effector T-Cell Responses and Associate with Metastatic Potential.
Chester Lai, Suzannah August, +9 authors, Eugene Healy.
Clin Cancer Res, 2016 Apr 02; 22(16). PMID: 27034329    Free PMC article.
Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer.
Ruth J Davis, Carter Van Waes, Clint T Allen.
Oral Oncol, 2016 May 25; 58. PMID: 27215705    Free PMC article.
Breaking Free of Control: How Conventional T Cells Overcome Regulatory T Cell Suppression.
Emily R Mercadante, Ulrike M Lorenz.
Front Immunol, 2016 Jun 01; 7. PMID: 27242798    Free PMC article.
The Costimulatory Receptor OX40 Inhibits Interleukin-17 Expression through Activation of Repressive Chromatin Remodeling Pathways.
Xiang Xiao, Xiaomin Shi, +7 authors, Xian Chang Li.
Immunity, 2016 Jun 19; 44(6). PMID: 27317259    Free PMC article.
Are Regulatory T Cells Defective in Type 1 Diabetes and Can We Fix Them?
Anabelle Visperas, Dario A A Vignali.
J Immunol, 2016 Nov 07; 197(10). PMID: 27815439    Free PMC article.
Soluble OX40L and JAG1 Induce Selective Proliferation of Functional Regulatory T-Cells Independent of canonical TCR signaling.
Prabhakaran Kumar, Khaled Alharshawi, +6 authors, Bellur S Prabhakar.
Sci Rep, 2017 Jan 04; 7. PMID: 28045060    Free PMC article.
New Immunotherapy Strategies in Breast Cancer.
Lin-Yu Yu, Jie Tang, +4 authors, Xiao-Ping Chen.
Int J Environ Res Public Health, 2017 Jan 14; 14(1). PMID: 28085094    Free PMC article.
TNF superfamily receptor OX40 triggers invariant NKT cell pyroptosis and liver injury.
Peixiang Lan, Yihui Fan, +9 authors, Xian Chang Li.
J Clin Invest, 2017 Apr 25; 127(6). PMID: 28436935    Free PMC article.
T Cells Deficient in the Tyrosine Phosphatase SHP-1 Resist Suppression by Regulatory T Cells.
Emily R Mercadante, Ulrike M Lorenz.
J Immunol, 2017 May 28; 199(1). PMID: 28550200    Free PMC article.
Intratumoral delivery of tumor antigen-loaded DC and tumor-primed CD4+ T cells combined with agonist α-GITR mAb promotes durable CD8+ T-cell-dependent antitumor immunity.
Zuqiang Liu, Xingxing Hao, +5 authors, Zhaoyang You.
Oncoimmunology, 2017 Jul 07; 6(6). PMID: 28680744    Free PMC article.
Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40.
David J Messenheimer, Shawn M Jensen, +6 authors, Bernard A Fox.
Clin Cancer Res, 2017 Sep 01; 23(20). PMID: 28855348    Free PMC article.
Highly Cited.
Combined OX40L and mTOR blockade controls effector T cell activation while preserving Treg reconstitution after transplant.
Victor Tkachev, Scott N Furlan, +15 authors, Leslie S Kean.
Sci Transl Med, 2017 Sep 22; 9(408). PMID: 28931653    Free PMC article.
Exploring Synergy in Combinations of Tumor-Derived Vaccines That Harbor 4-1BBL, OX40L, and GM-CSF.
Andrea J Manrique-Rincón, Camila M Beraldo, Jessica M Toscaro, Marcio C Bajgelman.
Front Immunol, 2017 Oct 05; 8. PMID: 28974950    Free PMC article.
CD27-Mediated Regulatory T Cell Depletion and Effector T Cell Costimulation Both Contribute to Antitumor Efficacy.
Anna Wasiuk, James Testa, +9 authors, Li-Zhen He.
J Immunol, 2017 Nov 08; 199(12). PMID: 29109120    Free PMC article.
Constitutive expression of NF-κB inducing kinase in regulatory T cells impairs suppressive function and promotes instability and pro-inflammatory cytokine production.
Fanny Polesso, Minhazur Sarker, +2 authors, Susan E Murray.
Sci Rep, 2017 Nov 09; 7(1). PMID: 29116141    Free PMC article.
Combination therapy with an OX40L fusion protein and a vaccine targeting the transcription factor twist inhibits metastasis in a murine model of breast cancer.
Anthony S Malamas, Scott A Hammond, Jeffrey Schlom, James W Hodge.
Oncotarget, 2017 Dec 07; 8(53). PMID: 29207606    Free PMC article.
Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.
Mariona Cabo, Rienk Offringa, +3 authors, Lorenzo Galluzzi.
Oncoimmunology, 2017 Dec 07; 6(12). PMID: 29209572    Free PMC article.
Tolerogenic nanoparticles restore the antitumor activity of recombinant immunotoxins by mitigating immunogenicity.
Ronit Mazor, Emily M King, +6 authors, Ira Pastan.
Proc Natl Acad Sci U S A, 2018 Jan 10; 115(4). PMID: 29311317    Free PMC article.
Eradication of spontaneous malignancy by local immunotherapy.
Idit Sagiv-Barfi, Debra K Czerwinski, +4 authors, Ronald Levy.
Sci Transl Med, 2018 Feb 02; 10(426). PMID: 29386357    Free PMC article.
Highly Cited.
Augmentation of CD134 (OX40)-dependent NK anti-tumour activity is dependent on antibody cross-linking.
Anna H Turaj, Kerry L Cox, +10 authors, Sean H Lim.
Sci Rep, 2018 Feb 06; 8(1). PMID: 29396470    Free PMC article.
Harnessing the immune system in the battle against breast cancer.
Elizabeth S Nakasone, Sara A Hurvitz, Kelly E McCann.
Drugs Context, 2018 Feb 20; 7. PMID: 29456568    Free PMC article.
Phenotypic and Functional Properties of Tumor-Infiltrating Regulatory T Cells.
Gap Ryol Lee.
Mediators Inflamm, 2018 Feb 22; 2017. PMID: 29463952    Free PMC article.
Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein.
Michael D Oberst, Catherine Augé, +19 authors, Scott A Hammond.
Mol Cancer Ther, 2018 Mar 17; 17(5). PMID: 29545330    Free PMC article.
Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer.
Nicholas Borcherding, Ryan Kolb, +3 authors, Weizhou Zhang.
J Mol Biol, 2018 May 26; 430(14). PMID: 29800567    Free PMC article.
Strategies to Genetically Modulate Dendritic Cells to Potentiate Anti-Tumor Responses in Hematologic Malignancies.
Annelisa M Cornel, Niek P van Til, Jaap Jan Boelens, Stefan Nierkens.
Front Immunol, 2018 Jun 06; 9. PMID: 29867960    Free PMC article.
Foxp3+ T Regulatory Cells: Still Many Unanswered Questions-A Perspective After 20 Years of Study.
Ethan M Shevach.
Front Immunol, 2018 Jun 06; 9. PMID: 29868011    Free PMC article.
Highly Cited. Review.
The promise and challenges of immune agonist antibody development in cancer.
Patrick A Mayes, Kenneth W Hance, Axel Hoos.
Nat Rev Drug Discov, 2018 Jun 16; 17(7). PMID: 29904196
Highly Cited. Review.
Fatty acid metabolism complements glycolysis in the selective regulatory T cell expansion during tumor growth.
Ilenia Pacella, Claudio Procaccini, +17 authors, Silvia Piconese.
Proc Natl Acad Sci U S A, 2018 Jun 27; 115(28). PMID: 29941600    Free PMC article.
Highly Cited.
OX40 Costimulation Inhibits Foxp3 Expression and Treg Induction via BATF3-Dependent and Independent Mechanisms.
Xiaolong Zhang, Xiang Xiao, +9 authors, Xian C Li.
Cell Rep, 2018 Jul 19; 24(3). PMID: 30021159    Free PMC article.
Interleukin-33 Contributes to the Induction of Th9 Cells and Antitumor Efficacy by Dectin-1-Activated Dendritic Cells.
Jintong Chen, Yinghua Zhao, +8 authors, Siqing Wang.
Front Immunol, 2018 Aug 16; 9. PMID: 30108595    Free PMC article.
New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1.
Nicolas Villanueva, Lyudmila Bazhenova.
Ther Adv Respir Dis, 2018 Sep 15; 12. PMID: 30215300    Free PMC article.
OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis.
Patrizia Nanni, Carla De Giovanni, +7 authors, Pier-Luigi Lollini.
Oncoimmunology, 2018 Sep 18; 7(8). PMID: 30221061    Free PMC article.
Expression of the Immune Checkpoint Modulator OX40 in Acute Lymphoblastic Leukemia Is Associated with BCR-ABL Positivity.
Kathrin Rothfelder, Ilona Hagelstein, +6 authors, Daniela Dörfel.
Neoplasia, 2018 Oct 10; 20(11). PMID: 30300827    Free PMC article.
Regulatory T Cells in Systemic Sclerosis.
Camelia Frantz, Cedric Auffray, Jerome Avouac, Yannick Allanore.
Front Immunol, 2018 Oct 31; 9. PMID: 30374354    Free PMC article.
High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer.
Erminia Massarelli, Vincent K Lam, +13 authors, John V Heymach.
J Immunother Cancer, 2019 Dec 18; 7(1). PMID: 31843013    Free PMC article.
T-Regulatory Cells In Tumor Progression And Therapy.
Amit Verma, Rohit Mathur, +3 authors, Bilikere S Dwarakanath.
Cancer Manag Res, 2020 Jan 11; 11. PMID: 31920383    Free PMC article.
Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model.
Carla De Giovanni, Giordano Nicoletti, +3 authors, Patrizia Nanni.
Cancers (Basel), 2019 Dec 01; 11(12). PMID: 31783695    Free PMC article.
Immune checkpoint modulation enhances HIV-1 antibody induction.
Todd Bradley, Masayuki Kuraoka, +27 authors, Barton F Haynes.
Nat Commun, 2020 Feb 23; 11(1). PMID: 32075963    Free PMC article.
Therapeutic strategies for the costimulatory molecule OX40 in T-cell-mediated immunity.
Yu Fu, Qing Lin, Zhirong Zhang, Ling Zhang.
Acta Pharm Sin B, 2020 Mar 07; 10(3). PMID: 32140389    Free PMC article.
The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia.
Patrick Williams, Sreyashi Basu, +22 authors, Naval G Daver.
Cancer, 2018 Dec 01; 125(9). PMID: 30500073    Free PMC article.
Highly Cited.
Stimulating T Cells Against Cancer With Agonist Immunostimulatory Monoclonal Antibodies.
Xue Han, Matthew D Vesely.
Int Rev Cell Mol Biol, 2019 Jan 13; 342. PMID: 30635089    Free PMC article.
Treg cells in autoimmunity: from identification to Treg-based therapies.
Lisa Göschl, Clemens Scheinecker, Michael Bonelli.
Semin Immunopathol, 2019 Apr 07; 41(3). PMID: 30953162
The promise of CD4+FoxP3+ regulatory T-cell manipulation in vivo: applications for allogeneic hematopoietic stem cell transplantation.
Sabrina Copsel, Dietlinde Wolf, Krishna V Komanduri, Robert B Levy.
Haematologica, 2019 Jun 22; 104(7). PMID: 31221786    Free PMC article.
In situ vaccination with defined factors overcomes T cell exhaustion in distant tumors.
Danny N Khalil, Nathan Suek, +18 authors, Taha Merghoub.
J Clin Invest, 2019 Jul 23; 129(8). PMID: 31329159    Free PMC article.
Molecular Links between Central Obesity and Breast Cancer.
Alina-Andreea Zimta, Adrian Bogdan Tigu, +3 authors, Ioana Berindan-Neagoe.
Int J Mol Sci, 2019 Oct 31; 20(21). PMID: 31661891    Free PMC article.
Co-Stimulatory Receptors in Cancers and Their Implications for Cancer Immunotherapy.
Seongju Jeong, Su-Hyung Park.
Immune Netw, 2020 Mar 12; 20(1). PMID: 32158591    Free PMC article.
Targeting the Antibody Checkpoints to Enhance Cancer Immunotherapy-Focus on FcγRIIB.
Ingrid Teige, Linda Mårtensson, Björn L Frendéus.
Front Immunol, 2019 Apr 02; 10. PMID: 30930905    Free PMC article.
New pathways in immune stimulation: targeting OX40.
Carolina Alves Costa Silva, Francesco Facchinetti, Bertrand Routy, Lisa Derosa.
ESMO Open, 2020 May 12; 5(1). PMID: 32392177    Free PMC article.
Co-stimulatory and co-inhibitory pathways in cancer immunotherapy.
Rachel E O'Neill, Xuefang Cao.
Adv Cancer Res, 2019 Jun 17; 143. PMID: 31202358    Free PMC article.
Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma.
Veronica Mollica, Alessandro Rizzo, +9 authors, Francesco Massari.
Cancers (Basel), 2020 Jun 06; 12(6). PMID: 32498352    Free PMC article.
Tumor necrosis factor receptor family costimulation increases regulatory T-cell activation and function via NF-κB.
Martina Lubrano di Ricco, Emilie Ronin, +8 authors, Benoît L Salomon.
Eur J Immunol, 2020 Feb 06; 50(7). PMID: 32012260    Free PMC article.
Combinatorial approach to cancer immunotherapy: strength in numbers.
Anna E Vilgelm, Douglas B Johnson, Ann Richmond.
J Leukoc Biol, 2016 Jun 04; 100(2). PMID: 27256570    Free PMC article.
The clinical promise of immunotherapy in triple-negative breast cancer.
Praveen Vikas, Nicholas Borcherding, Weizhou Zhang.
Cancer Manag Res, 2018 Dec 24; 10. PMID: 30573992    Free PMC article.
The Therapeutic Strategies of Regulatory T Cells in Malignancies and Stem Cell Transplantations.
Rana G Zaini, Amani A Al-Rehaili.
J Oncol, 2019 Jan 30; 2019. PMID: 30693029    Free PMC article.
OX40 and OX40L protein expression of tumor infiltrating lymphocytes in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers.
Yayi He, Xiaoshen Zhang, +6 authors, Caicun Zhou.
Transl Lung Cancer Res, 2019 Sep 27; 8(4). PMID: 31555511    Free PMC article.
FcγRIIB engagement drives agonistic activity of Fc-engineered αOX40 antibody to stimulate human tumor-infiltrating T cells.
Lucia Campos Carrascosa, Adriaan A van Beek, +19 authors, Jaap Kwekkeboom.
J Immunother Cancer, 2020 Sep 10; 8(2). PMID: 32900860    Free PMC article.
OX40-enhanced tumor rejection and effector T cell differentiation decreases with age.
Carl E Ruby, Andrew D Weinberg.
J Immunol, 2009 Jan 22; 182(3). PMID: 19155495    Free PMC article.
Expression of costimulatory TNFR2 induces resistance of CD4+FoxP3- conventional T cells to suppression by CD4+FoxP3+ regulatory T cells.
Xin Chen, Ryoko Hamano, +3 authors, Joost J Oppenheim.
J Immunol, 2010 Jun 08; 185(1). PMID: 20525892    Free PMC article.
CD4+CD25+ Regulatory T Cells Inhibit Natural Killer Cell Hepatocytotoxicity of Hepatitis B Virus Transgenic Mice via Membrane-Bound TGF-β and OX40.
Yongyan Chen, Rui Sun, +3 authors, Zhigang Tian.
J Innate Immun, 2015 Jun 13; 8(1). PMID: 26067079    Free PMC article.
Current Progresses and Challenges of Immunotherapy in Triple-Negative Breast Cancer.
Karan Mediratta, Sara El-Sahli, Vanessa D'Costa, Lisheng Wang.
Cancers (Basel), 2020 Dec 02; 12(12). PMID: 33256070    Free PMC article.
Immune-Checkpoint Inhibitors in B-Cell Lymphoma.
Marc Armengol, Juliana Carvalho Santos, +3 authors, Gaël Roué.
Cancers (Basel), 2021 Jan 13; 13(2). PMID: 33430146    Free PMC article.
Immune profiling of pituitary tumors reveals variations in immune infiltration and checkpoint molecule expression.
Yu Mei, Wenya Linda Bi, +8 authors, Ian F Dunn.
Pituitary, 2021 Jan 26; 24(3). PMID: 33492612
Immune profiling and immunotherapeutic targets in pancreatic cancer.
Felicia L Lenzo, Shumei Kato, +8 authors, Carl Morrison.
Ann Transl Med, 2021 Feb 12; 9(2). PMID: 33569421    Free PMC article.
OX40 as a novel target for the reversal of immune escape in colorectal cancer.
Lin-Hai Yan, Xiao-Liang Liu, +3 authors, Wei-Zhong Tang.
Am J Transl Res, 2021 Apr 13; 13(3). PMID: 33841630    Free PMC article.
Immune Modulation Plus Tumor Ablation: Adjuvants and Antibodies to Prime and Boost Anti-Tumor Immunity In Situ.
Renske J E van den Bijgaart, Fabian Schuurmans, +3 authors, Gosse J Adema.
Front Immunol, 2021 May 04; 12. PMID: 33936033    Free PMC article.
Regulation of mRNA stability by RBPs and noncoding RNAs contributing to the pathogenicity of Th17 cells.
Yiwei Zhang, Zhiyuan Wei, +6 authors, Yi Tian.
RNA Biol, 2020 Dec 12; 18(5). PMID: 33302787    Free PMC article.
CD40 Activity on Mesenchymal Cells Negatively Regulates OX40L to Maintain Bone Marrow Immune Homeostasis Under Stress Conditions.
Barbara Bassani, Claudio Tripodo, +12 authors, Sabina Sangaletti.
Front Immunol, 2021 Jun 05; 12. PMID: 34084166    Free PMC article.
OX40 agonist combined with irreversible electroporation synergistically eradicates established tumors and drives systemic antitumor immune response in a syngeneic pancreatic cancer model.
Qi-Wei Zhang, Xiao-Xia Guo, +4 authors, Xiao-Yi Ding.
Am J Cancer Res, 2021 Jul 13; 11(6). PMID: 34249428    Free PMC article.
Boosting Antitumor Response by Costimulatory Strategies Driven to 4-1BB and OX40 T-cell Receptors.
Daniele E Mascarelli, Rhubia S M Rosa, +5 authors, Marcio C Bajgelman.
Front Cell Dev Biol, 2021 Jul 20; 9. PMID: 34277638    Free PMC article.
Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies.
Hiroyoshi Nishikawa, Shohei Koyama.
J Immunother Cancer, 2021 Aug 01; 9(7). PMID: 34330764    Free PMC article.
Preclinical and clinical progress for HDAC as a putative target for epigenetic remodeling and functionality of immune cells.
Sijia Zhang, Lingjun Zhan, +3 authors, Haiping Zhao.
Int J Biol Sci, 2021 Sep 14; 17(13). PMID: 34512154    Free PMC article.
OX40-targeted immune agonist antibodies induce potent antitumor immune responses without inducing liver damage in mice.
Yee C Tee, Stephen J Blake, David J Lynn.
FASEB Bioadv, 2021 Oct 12; 3(10). PMID: 34632317    Free PMC article.
Spatial Mapping and Immunomodulatory Role of the OX40/OX40L Pathway in Human Non-Small Cell Lung Cancer.
Angelo Porciuncula, Micaela Morgado, +5 authors, Kurt A Schalper.
Clin Cancer Res, 2021 Sep 15; 27(22). PMID: 34518312    Free PMC article.
Tnfrsf4-expressing regulatory T cells promote immune escape of chronic myeloid leukemia stem cells.
Magdalena Hinterbrandner, Viviana Rubino, +6 authors, Carsten Riether.
JCI Insight, 2021 Nov 03; 6(23). PMID: 34727093    Free PMC article.
Approaches of the Innate Immune System to Ameliorate Adaptive Immunotherapy for B-Cell Non-Hodgkin Lymphoma in Their Microenvironment.
Takashi Watanabe.
Cancers (Basel), 2022 Jan 12; 14(1). PMID: 35008305    Free PMC article.
The Pyroptosis-Related Gene Signature Predicts the Prognosis of Hepatocellular Carcinoma.
Shuqiao Zhang, Xinyu Li, +3 authors, Weihong Kuang.
Front Mol Biosci, 2022 Jan 21; 8. PMID: 35047554    Free PMC article.
Boosting antitumor response with PSMA-targeted immunomodulatory VLPs, harboring costimulatory TNFSF ligands and GM-CSF cytokine.
Soledad Palameta, Andrea J Manrique-Rincón, +6 authors, Marcio C Bajgelman.
Mol Ther Oncolytics, 2022 Mar 15; 24. PMID: 35284623    Free PMC article.
Addressing the Elephant in the Immunotherapy Room: Effector T-Cell Priming versus Depletion of Regulatory T-Cells by Anti-CTLA-4 Therapy.
Megan M Y Hong, Saman Maleki Vareki.
Cancers (Basel), 2022 Mar 26; 14(6). PMID: 35326731    Free PMC article.
Prevalence of intratumoral regulatory T cells expressing neuropilin-1 is associated with poorer outcomes in patients with cancer.
Christopher A Chuckran, Anthony R Cillo, +26 authors, Dario A A Vignali.
Sci Transl Med, 2021 Dec 09; 13(623). PMID: 34878821    Free PMC article.